Sino Biological has successfully completed the acquisition of SignalChem Biotech, a Canadian biotech firm, for $48 million, a step that enhances its portfolio and solidifies its presence on a global scale. Initially agreed upon in October 2023, the transaction brings together two entities focused on enzyme bioreagent development, production, and related contract research services. SignalChem, known for its work in bioactive enzymes such as kinases and proteases, will now function as a wholly-owned subsidiary under Sino Biological, providing the latter with unique capabilities in enzyme production. Dr. Jie Zhang, President and General Manager of Sino Biological, emphasized the significance of SignalChem’s leading-edge scientific work, noting its alignment with Sino Biological’s standing in bioactive recombinant proteins. The merger anticipates a more comprehensive range of products and services for the life sciences community, driving forward the quest for new treatments, vaccines, and diagnostics. For SignalChem, whose co-founder, president, and CEO Jun Yan expressed enthusiasm about the merger, the deal represents an opportunity for heightened innovation and collaboration. This strategic alliance aims to fuse the strengths and resources of both companies to tackle the demanding challenges researchers face globally.
Biotechnology, Pharmaceuticals, Mergers and Acquisitions,Canada, China
https://mergersacquisitions.einnews.com/article/707369857/H_DgJ-ddwrtc-geB?ref=rss&ecode=Q1vNcweEggLWKz7L